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Pyruvate dehydrogenase kinase (PDK) isoforms
are molecular switches that downregulate the
pyruvate dehydrogenase complex (PDC) by re-
versible phosphorylation in mitochondria. We
have determined structures of human PDK1 or
PDK3 bound to the inhibitors AZD7545, dichlor-
oacetate (DCA), and radicicol. We show that the
trifluoromethylpropanamide end of AZD7545
projects into the lipoyl-binding pocket of
PDK1. This interaction results in inhibition of
PDK1 and PDK3 activities by aborting kinase
binding to the PDC scaffold. Paradoxically,
AZD7545 at saturating concentrations robustly
increases scaffold-free PDK3 activity, similar
to the inner lipoyl domain. Good DCA density
is present in the helix bundle in the N-terminal
domain of PDK1. Bound DCA promotes local
conformational changes that are communi-
cated to both nucleotide-binding and lipoyl-
binding pockets of PDK1, leading to the inacti-
vation of kinase activity. Finally, radicicol
inhibits kinase activity by binding directly to
the ATP-binding pocket of PDK3, similar to
Hsp90 and Topo VI from the same ATPase/
kinase superfamily.
INTRODUCTION
The pyruvate dehydrogenase complex (PDC) is a mem-
ber of the highly conserved mitochondrial a-ketoacid
dehydrogenase complexes comprising the PDC, the
branched-chain a-ketoacid dehydrogenase complex
(BCKDC), and the a-ketoglutarate dehydrogenase com-
plex (Patel and Roche, 1990; Reed, 2001). PDC catalyzes
the oxidative decarboxylation of pyruvate to give rise to
acetyl-CoA, linking glycolysis to the Krebs cycle. The
9 3 106 dalton mammalian PDC is organized around
a 60-meric dodecahedral core consisting of acetyltrans-
ferase (E2p) and E3-binding protein (E3BP) (Hiromasa992 Structure 15, 992–1004, August 2007 ª2007 Elsevier Ltd Alet al., 2004). Through N-terminal peripheral domains of
the two constituent proteins, the E2p/E3BP core binds
multiple copies of pyruvate dehydrogenase (E1p),
dihydrolipoamide dehydrogenase (E3), pyruvate dehydro-
genase kinase (PDK), and pyruvate dehydrogenase
phosphatase (PDP) (Reed, 2001).
The mammalian PDC is tightly regulated by reversible
phosphorylation. The phosphorylation of specific serine
residues in E1p by PDK results in the inactivation of PDC,
whereas the dephosphorylation by PDP restores PDC
activity (Harris et al., 2001; Holness and Sugden, 2003).
Phosphorylation of E1p occurs at three serine residues
(Ser264, site 1; Ser271, site 2; and Ser203, site 3) (Sale
and Randle, 1981; Teague et al., 1979; Yeaman et al.,
1978), although phosphorylation of each site alone inacti-
vates PDC (Kolobova et al., 2001; Korotchkina and Patel,
2001a). To date, four PDK isoforms (1–4) in human
mitochondria have been identified (Popov et al., 1997).
Each PDK isoform exhibits different site specificity: all
four isoforms phosphorylate sites 1 and 2 at different rates
(for site 1,PDK2>PDK4zPDK1>PDK3; for site 2,PDK3>
PDK4 > PDK2 > PDK1), but only PDK1 modifies site 3
(Kolobova et al., 2001; Korotchkina and Patel, 2001b).
PDKs are recruited to the PDC by preferentially binding
to the inner lipoyl (L2) domain of the E2p subunit in the
E2p/E3BP core (Liu et al., 1995; Patel and Roche, 1990).
Binding of PDKs to the L2 domain requires a lipoyl group
covalently attached to Lys173 of L2 (Radke et al., 1993).
Colocalization of PDK with the E1p substrate bound to
the E1-binding domain (immediately downstream of L2)
of E2p results in enhanced PDK activity. Individual
isoforms exhibit different binding affinities for L2, with
PDK3 > PDK1 z PDK2 > PDK4 (Tuganova et al., 2002).
PDK3, which binds to L2most tightly, is robustly activated
by the E2p/E3BP core; the majority of this activation is
achieved by binding to isolated L2 (Baker et al., 2000;
Roche et al., 2003). PDK1 and PDK2 activities are aug-
mented by the E2p/E3BP core by 2.5-fold and 10-fold,
respectively, but not by binding to L2 alone (Baker et al.,
2000; Roche and Hiromasa, 2007). PDK4 has the lowest
affinity for L2, and is only minimally stimulated by the
E2p/E3BP core (Roche and Hiromasa, 2007).
Mitochondrial protein kinases comprising PDKs and the
related BCKD kinase (BCK) constitute a novel family ofl rights reserved
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Structural Mechanisms for PDK Inhibitorsprotein kinases (Popov et al., 1997), in which motifs that
normally occur in eukaryotic Ser/Thr/Tyr kinases (Hanks
et al., 1988) are absent. Structural studies of PDK and
BCK have revealed that these kinases consist of two
distinct domains: the N- and C-terminal domains (Kato
et al., 2005; Machius et al., 2001; Steussy et al., 2001).
The N-terminal domain of PDK (or B domain in BCK)
consists of eight a helices with a four-helix bundle-like
structure forming the core. The C-terminal domain (or K
domain in BCK) contains the phosphotransfer catalytic
site whose architecture is conserved in the GHKL
ATPase/kinase superfamily including DNA gyrase B,
Hsp90, histidine kinases, and MutL (Dutta and Inouye,
2000). Members of this superfamily share four conserved
motifs (N, G1, G2, and G3 boxes), which form a unique
ATP-binding fold (Alex and Simon, 1994; Bergerat et al.,
1997; Dutta and Inouye, 2000; Smirnova et al., 1998).
This fold includes a common structural element known
as the ‘‘ATP lid,’’ whose conformational change is coupled
to both ATP hydrolysis and protein-protein interactions
(Ban et al., 1999; Machius et al., 2001; Wigley et al.,
1991). The crystal structure of the PDK3-L2 complex has
revealed that L2 binds to the lipoyl-binding pocket in the
N-terminal domain of PDK3. This binding causes the
open conformation of the active-site cleft in PDK3, in
contrast to the closed conformation of rat PDK2 free
from L2 (Kato et al., 2005; Steussy et al., 2001). The
open active-site cleft destabilizes the ATP lid located
inside the ATP-binding pocket of PDK3, which facilitates
an ADP/ATP exchange to remove product inhibition
exerted by ADP.
PDK isoforms exhibit tissue-specific expression; PDK1
is detected in heart, pancreatic islets, and skeletal mus-
cles; PDK2 is expressed in all tissues; PDK3 is present
in testes, kidney, and brain; and PDK4 is abundant in
heart, skeletal muscle, kidney, and pancreatic islets
(Bowker-Kinley et al., 1998). The expression of PDK2
and PDK4 is induced in starvation and diabetes, which is
Figure 1. Molecular Structures of PDK Inhibitors AZD7545,
Dichloroacetate, and RadicicolStructure 15, 992–reversed by insulin treatment (Harris et al., 2001; Wu
et al., 1998). Impaired insulin-induced downregulation of
PDK4 (due to the lack of insulin or insensitivity to insulin)
leads to the overexpression of PDK4 and shuts off glucose
oxidation in diabetic animals (Holness and Sugden, 2003;
Roche et al., 2003). Therefore, PDK4 is a potential drug
target for the treatment of type II diabetes. Furthermore,
very recent studies from three different groups showed
that PDK1 is specifically upregulated by HIF-1 in hypoxic
cancer cells, which in turn reduces PDC activity (Kim
et al., 2006; Koukourakis et al., 2005; Papandreou et al.,
2006). Thus, PDK1 was suggested to be a potential target
for antitumor therapies (Pan andMak, 2007; Simon, 2006).
Selective inactivation of PDK isoforms by the specific
inhibitor dichloroacetate (DCA) has been shown to dere-
press a mitochondrial potassium-ion channel axis, trigger
apoptosis in cancer cells, and inhibit tumor growth
(Bonnet et al., 2007; Cairns et al., 2007).
Among known synthetic inhibitors for PDK, the pyruvate
analog DCA (Figure 1) is the most common classic
inhibitor for PDK isoforms (Bersin and Stacpoole, 1997;
Whitehouse et al., 1974), and has been shown to have
beneficial effects in diabetes, lactic acidosis, andmyocar-
dial ischemia (Bersin and Stacpoole, 1997; Henderson
et al., 1997; Stacpoole, 1989). Biochemical studies
indicated that DCA and ADP synergistically inhibit activi-
ties of PDK isoforms (Bao et al., 2004; Pratt and Roche,
1979). Recentmutational analyses and the PDK2 structure
in complex with DCA revealed that DCA binds to the N-
terminal domain of PDK2 (Klyuyeva et al., 2007; Knoechel
et al., 2006). However, the inhibition mechanism of DCA is
not known, as no structural change in PDK2was observed
upon DCA binding. The glucose-lowering compound
AZD7545, (2R)-N-{4-[4-(dimethylcarbamoyl)phenylsul-
fonyl]-2-chlorophenyl}-3,3,3-trifluoro-2-hydroxy-2-meth-
ylpropanamide (Figure 1), manufactured by AstraZeneca,
UK, has been shown to inhibit PDK2, resulting in
enhanced glucose breakdown through the PDC flux in
tissues from diabetic animals (Mayers et al., 2005; Morrell
et al., 2003). The related inhibitors AZ12 and Nov3r were
shown to bind to the lipoyl-binding pocket in the N-termi-
nal domain of PDK2 (Knoechel et al., 2006). Therefore, it
would appear that this group of compounds indirectly ex-
erts its inhibitory effect by preventing PDK from binding to
the E2p/E3BP core. Finally, the antitumor compound rad-
icicol (Figure 1) inhibits the activities of Hsp90 and Topo VI
by blocking ATP binding to these enzymes (Corbett and
Berger, 2005; Roe et al., 1999). PDK2 and related BCK
are also inhibited by radicicol (Besant et al., 2002; Tuga-
nova et al., 2001). As PDK and BCK are members of the
GHKL ATPase/kinase superfamily, which includes Hsp90
and Topo VI, it has been proposed that radicicol inhibits
PDK isoforms in the same manner as it inhibits Hsp90
and Topo VI (Tuganova et al., 2001).
To provide the structural basis for the inhibitory mecha-
nism of PDKs by these three classes of synthetic inhibi-
tors, we have determined the crystal structures of the
human PDK1-AZD7545, PDK1-DCA, and PDK3-L2-
radicicol complexes.1004, August 2007 ª2007 Elsevier Ltd All rights reserved 993
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Structural Mechanisms for PDK InhibitorsFigure 2. Inhibition of PDK1 and PDK3 Activities by AZD7545, Radicicol, and DCA
(A) IC50 for AZD7545, SUMO-PDK1, or SUMO-PDK3 (50 nM each) in the presence of E1p bound to the E2p/E3BP core was titrated with increasing
concentrations of AZD7545 in 2% DMSO as indicated. Following an incubation of 30 min, residual kinase activity was assayed as described in
Experimental Procedures. PDK activity is expressed as % maximal (8.2 nmol/min/mg for PDK1; 63.6 nmol/min/mg for PDK3; both measured in
2% DMSO). Inhibition curves were fitted and IC50 values were obtained using the Prism program (GraphPad Software, San Diego, CA, USA).
(B) IC50 for radicicol. For titrations with radicicol, 0.56 mM SUMO-PDK1 or 0.28 mM SUMO-PDK3 was used. The remaining conditions are also
described in Experimental Procedures.
(C) Inhibition of PDK1 and PDK3 by AZD7545, DCA, and radicicol with the E1p substrate on the E2p/E3BP core. Inhibitor concentrations used were
5- to 40-fold higher than the respective IC50 or Ki values. Following incubation for 30 min, kinase activity was assayed as in (A), and residual activity
levels are expressed as%control. Control activities for PDK1 and PDK3 in 2%DMSO are as in (A). Control activity without DMSO for DCA inhibition is
9.7 nmol/min/mg for PDK1 and 91.9 nmol/min/mg for PDK3. The bars in (C) and (D) represent averages of two independent experiments.
(D) Inhibition of PDK1 and PDK3 in the absence of the E2p/E3BP core. Basal kinase activities were assayed with free E1p as a substrate, with the
remaining conditions as in (A). Control activities in 2% DMSO for AZD7545 and radicicol inhibitions are 6.3 nmol/min/mg for PDK1 and 5.7 nmol/
min/mg for PDK3. Control activities without DMSO for DCA inhibition are 6.4 nmol/min/mg for PDK1 and 4.9 nmol/min/mg for PDK3. Note that scales
on the ordinates (relative activity, % control) are different between (C) and (D).RESULTS AND DISCUSSION
Inhibition of Human PDK Isoforms
by Specific Inhibitors
We studied the inhibition of SUMO (small ubiquitin
modifier)-tagged PDK1 and SUMO-PDK3 activities by
AZD7545, DCA, and radicicol (Figure 2). To estimate the
half-maximal inhibitory concentration (IC50) for AZD7545,
PDK1 or PDK3 along with the E2p/E3BP core and the
pyruvate dehydrogenase (E1p) substrate were incubated
with increasing stoichiometric excesses of AZD7545 in994 Structure 15, 992–1004, August 2007 ª2007 Elsevier Ltd Al2% dimethyl sulfoxide (DMSO), followed by assays for
residual kinase activity. Under our assay conditions,
AZD7545 shows an IC50 of 87 nM for PDK1 and 600 nM
for PDK3 (Figure 2A). The IC50 for inhibition of PDK1 esti-
mated here is greater than 2-fold higher than that reported
previously (Morrell et al., 2003), but a lower kinase
concentration (40 nM versus 50 nM in the present study)
was used in the earlier work (R.M. Mayers, personal
communication), and IC50 values are enzyme concentra-
tion dependent. When measured similarly, radicicol
exhibits an IC50 of 230 mM for the inhibition of PDK1l rights reserved
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Structural Mechanisms for PDK Inhibitorsactivity (at 0.56 mM kinase concentration) and an IC50 of
400 mM for PDK3 (at 0.28 mM concentration) (Figure 2B).
We next determined the degree of inhibition of PDK1
and PDK3 activities by saturating concentrations of the
inhibitors, with either E1p bound to the E2p/E3BP core
(scaffold-dependent kinase activity) or free E1p (scaf-
fold-free kinase activity) as substrate. The concentrations
of the inhibitors AZD7545 and radicicol used were at least
10-fold higher than the respective IC50 values for PDK1
and PDK3 (Figures 2A and 2B). In the presence of the
E2p/E3BP core, AZD7545 at 10 mM reduces PDK1 and
PDK3 activities to 28% and 31% of the control, respec-
tively (Figure 2C). These data are consistent with an earlier
proposition that AZD7545 inhibits the E2p-dependent
stimulation of PDK2 activity (Morrell et al., 2003; Tuganova
et al., 2007). Paradoxically, when the E2p/E3BP core is
absent, AZD7545 stimulates scaffold-free basal PDK1
and PDK3 activities to 1.3-fold and 10-fold, respectively
(Figure 2D). The 10-fold increase in basal PDK3 activity
by AZD7545 is comparable to the fold increase of basal
PDK3 activity by the isolated L2 domain (Baker et al.,
2000; Kato et al., 2005). The significance of the robust
stimulation of basal PDK3 activity by AZD7545 will be
discussed.
With the E2p/E3BP core, DCA at 40 mM decreases
PDK1 and PDK3 activities to 4% and 28% of the control,
respectively (Figures 2C). A saturating DCA concentration
was used in the inhibition assay, based on the IC50 for DCA
of greater than 1 mM for PDK isoforms (Baker et al., 2000;
Bebernitz et al., 2000) and the apparent Ki of 1 mM and
8 mM for PDK1 and PDK3, respectively (Bowker-Kinley
et al., 1998). PDK3 with E2p was previously reported not
to be significantly inhibited by DCA; however, a nonsatu-
rating DCA concentration (1 mM) was used in those stud-
ies (Baker et al., 2000; Roche and Hiromasa, 2007). When
the E2p/E3BP scaffold-free activity was measured, DCA
similarly reduces PDK1 and PDK3 activities to 4% and
17% of the control, respectively (Figure 2D). In parallel,
radicicol at 4 mM inhibits the E2p/E3BP core-dependent
PDK1 and PDK3 activities to 4% and 2% of the control,
respectively (Figure 2C). With free E1p as a substrate,
the same concentration of radicicol reduces the scaf-
fold-free activities of PDK1 and PDK3 to 5% each of the
control. The similar degrees of inhibition by DCA and
radicicol both in the absence and presence of the E2p/
E3BP core suggest that these compounds mainly inhibit
the catalytic activity of the kinase. To provide the struc-
tural basis for the mechanisms of inactivation by these
inhibitors, we have determined the crystal structures of
apo-PDK1 as well as the PDK1-AZD7545, PDK1-DCA,
and PDK3-L2-radicicol complexes.
Crystal Structure of Human PDK1
The human PDK1 structure was determined maximally at
1.9 A˚ resolution (Figure 3A; Table 1; see Figure S1 in the
Supplemental Data available with this article online). The
three structures of PDK1 (apo, AZD7545-bound, and
DCA-bound) are virtually the same except that the struc-
ture of PDK1-DCA shows a small conformational changeStructure 15, 992–in the N-terminal domain (see below). The chain fold of
apo-PDK1 is similar to those of rat PDK2 (root-mean-
square deviation [rmsd] = 1.2 A˚ for 320 Ca atoms), human
PDK2 (rmsd = 1.3 A˚ for 329 Ca atoms), and human PDK3
in the PDK3-L2 complex (rmsd = 1.0 A˚ for 343 Ca atoms)
(Kato et al., 2005; Knoechel et al., 2006; Steussy et al.,
2001). A noticeable difference between PDK1 and the
other PDK isoforms is observed at the ATP-binding
pocket, where apo-PDK1 has a completely ordered ATP
lid (residues 336–356), whereas its equivalents in PDK2
and PDK3 are disordered to different extents depending
on the bound nucleotide state. The ATP lid in PDK1
projects outward, with Glu345 in the ATP lid forming
hydrogen bonds (H bonds) with Tyr4030 and Lys920 in
a symmetry-related molecule (Figure 3C). Arg348 in the
ATP lid also makes H bonds with Asp2410 and Asn2460
in a second symmetry-related molecule. Therefore,
when a nucleotide binds to the ATP-binding pocket, the
ordered ATP lid must be reorganized to accommodate
the phosphate group of the nucleotide. Significant crack-
ing of PDK1 crystals occurred upon soaking with ATP or
ADP, indicating that the above interactions are critical
for the crystal packing of apo-PDK1.
Another noticeable conformational change is in the C-
terminal tail of PDK1. The segment of residues 418–423
including the conserved residues Asp419 and Trp420 in
PDK1 (designated as a ‘‘DW’’ motif) hovers over the other
subunit of the dimer (Figures 3A and 3D). Both the side
chains and main chains of Asp419 and Trp420 interact
with residues Tyr1790, Arg1830, and Arg3990 in the other
subunit (Figure 3D). The DWmotif appears to be the linch-
pin that enables the C-terminal tail to anchor to the other
subunit in the PDK1 dimer. Several residues preceding
this segment and all the downstream residues are disor-
dered. Due to crystallographic two-fold symmetry, the
two C-terminal tails, each from one PDK1 subunit, cross
over to form a ‘‘crosstail’’ configuration in the dimer (Fig-
ure 3A). A similar configuration was first observed in the
structure of the PDK3-L2 complex, in which the fully
ordered C-terminal tail from one PDK3 subunit interacts
with the L2 bound to the lipoyl-binding pocket of the other
PDK3 subunit (Figure 3B) (Kato et al., 2005). This fully
ordered crosstail configuration locks PDK3 in the open
conformation, in which the active-site clefts of the both
PDK3 subunits are wider than the closed conformation
present in the rat PDK2 structure with completely disor-
dered C-terminal tails (Steussy et al., 2001). As described
before, PDK3 in the open conformation is far more active
than in the closed conformation, through an increased rate
of ATP/ADP exchange and presumably enhanced affinity
for the substrate E1p (Kato et al., 2005). Despite a lack
of bound L2, the partially ordered crosstails maintain the
open conformation in apo-PDK1 (Figure 3A). A similar
open conformation with the partial crosstail configuration
is also present in the apo and inhibitor-bound structures of
human PDK2 without L2 (Knoechel et al., 2006). We
suggest that in apo-PDK1 and apo-PDK2, the active sites
exist in equilibrium between the closed and open confor-
mations. The presence of bound L2 presumably locks the1004, August 2007 ª2007 Elsevier Ltd All rights reserved 995
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Structural Mechanisms for PDK InhibitorsFigure 3. Structures of PDK1 and PDK3-
L2 in Complex with Inhibitors
(A) The dimeric structures of apo-PDK1 with
superimposed AZD7545 and DCA bound to
PDK1. Each PDK1 subunit is represented as
a ribbon model (green and cyan). AZD7545
and DCA molecules bound to each PDK1
subunit are shown in space-filling models.
The fully ordered ATP lid is colored in yellow.
The partially ordered C-terminal tails in the
crossed configuration are colored in magenta.
(B) The PDK3-L2 dimer with radicicol bound to
the ATP-binding pocket. Both PDK3 subunits
are shown in green and cyan. The bound L2
domains are colored in yellow, with the lipoyl
group shown in a space-filling model. Radici-
col molecules bound to each PDK3 subunit
are also shown in the same model. The fully
ordered C-terminal tails are in magenta. The
red arrows in (A) and (B) indicate the active-
site clefts of these kinases. Stereo figures of
the Ca traces for the PDK1 and PDK3-L2 struc-
tures are shown in Figure S1.
(C) The close-up view of the fully ordered ATP
lid (yellow) from one PDK1 subunit (cyan).
Two symmetry-related PDK1 molecules are
shown in gray and pink, respectively. The
bound ATP in the structure of PDK3-L2-ATP
published earlier (PDB ID code 1Y8P; Kato
et al., 2005) is superimposed. Key residues
for holding the ordered conformation of the
ATP lid are shown in stick models.
(D) The interaction between the C-terminal tail from one PDK1 subunit (shown as a stick model in cyan) and the other subunit (shown as an electro-
static surface) in the dimer. The surface of the latter is colored in blue for the positive charge and in red for the negative charge. Dotted lines represent
disordered regions of the C-terminal tail.active sites in these PDK isoforms exclusively in the open
conformation. The binding of nucleotide and/or pyruvate
to human PDK2 reversibly displaces the DW motif, which
in turn hampers L2 binding to PDK2 (Hiromasa et al.,
2006). A loss of the crosstail configuration may promote
the transformation of the PDK structure from the open to
the closed conformation.
Extensive Interactions between AZD7545 and PDK1
The structure of the PDK1-AZD7545 complex shows that
the inhibitor AZD7545 binds to the lipoyl-binding pocket in
the N-terminal domain of PDK1 (Figures 4A–4C). The loop
between helices a2 and a3 is disordered in the apo-PDK1
structure, and AZD7545 binding imparts the ordering of
this loop (see Figure 5D). The interior of the lipoyl-binding
pocket in PDK1 is lined with highly conserved hydropho-
bic residues (Leu57, Phe62, Phe65, Phe78, Leu79,
Leu195, Leu201, and Phe202), which form a hydrophobic
interface with AZD7545 (Figure 4B). The two conserved
phenylalanine residues (Phe65 and Phe78) that sandwich
the 2-chlorophenyl group of the bound AZD7545 are
apparently important for this interaction. Indeed, Popov’s
group has recently reported that the corresponding
phenylalanine residues in PDK2 (Phe31 and Phe44) are
essential for the inhibition of PDK2 activity by AZD7545
(Tuganova et al., 2007). The conserved hydrophobic
residues in PDK3 interact exclusively with the lipoyl pros-996 Structure 15, 992–1004, August 2007 ª2007 Elsevier Ltd Athetic group of L2 (Kato et al., 2005). The superposition of
the structures of the PDK1-AZD7545 and PDK3-L2
complexes shows that AZD7545 binds to the lipoyl-bind-
ing pocket of PDK1 deeper than the lipoyl group of L2 in
the PDK3-L2 structure (Figure 4C). The trifluoromethyl
group of AZD7545 appears to be a mimesis of the acetyl
group condensed with the lipoyl group of L2 by E1p-cata-
lyzed reductive acetylation. The acetylated lipoyl L2
shows the highest affinity for PDK2 among the three differ-
ent forms of the L2 domain (oxidized, reduced, and acet-
ylated) (Roche et al., 2003). AZD7545 binding is further
fostered by H bonds that were not observed between
the lipoyl group of L2 and PDK3 in the PDK3-L2 structure
(Kato et al., 2005). The conserved Ser75 in PDK1 forms an
H bond with the hydroxyl group of the ligand (Figure 4B),
whereas in PDK2, the corresponding serine residue
(Ser41) forms H bonds with AZ12, a compound related
to AZD7545 and Nov3r (Knoechel et al., 2006). These H
bonds are likely a common feature for this class of inhibi-
tors for recognition by the lipoyl-binding pockets from
different PDK isoforms. A water molecule is trapped inside
the lipoyl-binding pocket of PDK1, which coordinates an
H-bonding network involving Phe62, Gln197, and the
amide oxygen of AZD7545 (Figure 4B). An equivalent
water molecule was also observed in the structure of
PDK2 in complex with AZ12 (Knoechel et al., 2006). There-
fore, it is tempting to suggest that a modified AZD7545ll rights reserved
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Structural Mechanisms for PDK InhibitorsTable 1. Data Collection and Refinement Statistics
Apo-PDK1 PDK1-AZD7545 PDK1-DCA PDK3-L2-Radicicol
Data Collectiona
Space group P41212 P41212 P41212 P6522
Unit cell (A˚)
a = b 98.19 96.98 98.32 120.87
c 110.40 111.35 110.60 239.64
Wavelength (A˚) 0.98 0.98 0.98 0.98
Resolution (A˚) 2.03 1.90 2.00 2.60
Unique reflections 34,783 42,222 37,074 32,612
Completeness (%) 97.6 (96.7) 99.3 (100) 99.4 (100) 100 (100)
Rmerge (%)
b 4.5 (53.6) 6.3 (43.4) 4.0 (56.1) 5.4 (69.4)
<I>/<s(I)> 41.9 (2.6) 29.6 (4.7) 38.1 (3.2) 33.4 (2.6)
Multiplicity 9.2 (5.8) 9.1 (8.7) 7.4 (7.8) 7.7 (7.1)
Refinementa
Number of reflections
(work/test)
33,007/1,737 38,495/2,058 34,295/1,802 30,887/1,647
Number of atoms (mean B value) (A˚2)
Protein 2,969 (53.6) 2,990 (30.7) 2,972 (43.6) 3,731 (55.6)
Solvents 212 (46.3) 315 (39.1) 242 (44.3) 81 (45.4)
Inhibitor — 31 (35.9) 6 (68.0) 25 (42.3)
Missing residue regions 30–40, 68–70, 168–169,
204–214, 415–416,
424–436
30–40, 168–169,
204–214, 415–416,
424–436
30–40, 68–70, 168–169,
204–214, 415–416,
424–436
9, 12, 172–175, 307–
324, 402–406 in PDK3;
126–127, 221–233 in L2
Rwork (%)
c 19.0 (24.2) 21.12 (36.3)d 23.0 (37.2)d 20.5 (33.3)
Rfree (%)
c 21.2 (31.5) 24.9 (42.1)d 27.7 (44.1)d 23.8 (39.4)
Rmsd
Bond length (A˚) 0.021 0.019 0.014 0.020
Bond angle () 1.527 1.696 1.378 1.820
Ramachandran plot
Most favored (%) 95.0 94.1 92.7 91.6
Allowed (%) 5.0 5.9 7.3 8.4
Disallowed (%) 0 0 0 0
a Values in parentheses refer to data in the highest resolution shell unless otherwise indicated.
b Rmerge =ShklSjjIj <I>j/ShklSjIj, where <I> is themean intensity of j observations from a reflection hkl and its symmetry equivalents.
c Rwork = ShkljjFobsj  kjFcalcjj/ShkljFobsj. Rfree = Rwork for 5% of reflections that were omitted from refinement.
dWe did not back-soak these crystals to remove excess AZD7545 and DCA. Because the scattering factor of the chloride atom is
relatively high, it is likely that excess AZD7545 or DCA, which contain one and two chloride atoms, respectively, results in higher
Rwork and Rfree values of the PDK-inhibitor crystals than those of the apo-PDK1 crystal.that directly forms H bonds with Phe62 and Gln197 may
show a significantly increased binding affinity for PDK1.
The portions of AZ12 and Nov3r that protrude outside of
the lipoyl-binding pocket are partially disordered and
project in different directions (Figure 4D) (Knoechel et al.,
2006). In contrast, the corresponding portion in
AZD7545 is fully ordered except for the twomethyl groups
at the amide end. This portion of AZD7545 is kinked
upward almost 90 at the sulfonyl group, and contactsStructure 15, 992–the molecular surface of PDK1. The corresponding
surface on PDK3 interacts with the C-terminal tail from
the other PDK3 subunit (Figure 4C).
It is significant that in the absence of the E2p/E3BP
core, AZD7545 stimulates basal PDK3 activity by 10-
fold, similar to that observed with the L2 domain
(Figure 2D) (Baker et al., 2000; Kato et al., 2005). The pres-
ent results suggest that the binding of the trifluoromethyl-
propanamide group of AZD7545 to the lipoyl-binding1004, August 2007 ª2007 Elsevier Ltd All rights reserved 997
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Structural Mechanisms for PDK InhibitorsFigure 4. Structure of AZD7545 Bound to
the Lipoyl-Binding Pocket of PDK1
(A) The omit electron density map of the bound
AZD7545. The density is superimposed on the
refined model of AZD7545 at a 3s level in blue
and a 9s level in red, with PDK1 shown in a
ribbon model. A water molecule trapped in
the lipoyl-binding pocket is shown as a red ball.
(B) Interactions of AZD7545 with PDK1 resi-
dues in the lipoyl-binding pocket. Hydrophobic
residues of PDK1 are shown in orange.
H bonds between AZD7545 and PDK residues
are indicated by dashed lines. The trapped
water molecule is shown as a red ball.
(C) Superimposition of bound AZD7545 in
PDK1 (green) on the lipoyl lysine residue of L2
(yellow) bound to PDK3 (magenta). The C-ter-
minal tail from the other PDK3 subunit is shown
in red. For clarity, helix a3 is removed.
(D) Superimposition of bound AZD7545 in
PDK1 (green) with AZ12 (yellow) and Nov3r
(cyan) bound to PDK2 (Knoechel et al., 2006).
Only residue numbers for PDK1 are indicated.
Stereo figures of (B) and (D) are provided in
Figure S2.pocket alone is able to markedly enhance scaffold-free
basal PDK3 activity. However, it is presently unclear how
the binding of AZD7545 robustly stimulates basal PDK3
activity, as no significant conformational changes are
observed in the PDK1-AZD7545 structure compared to
the apo-PDK1 structure, except for the stabilization of998 Structure 15, 992–1004, August 2007 ª2007 Elsevier Ltd Althe lipoyl-binding pocket (see Table 2). The absence of
significant reconfigurations in the PDK1-AZD7545 struc-
ture is consistent with a marginal stimulation (1.3-fold) of
basal PDK1 activity by AZD7545 (Figure 2D). On the other
hand, under physiological conditions, PDK3 is tightly
bound to the E2p/E3BP scaffold of the mammalian PDCFigure 5. Structure of the DCA-Binding
Site in PDK1
(A) The DCA-binding site in the central core of
the helix bundle in the PDK1 N-terminal do-
main. The omit electron density map is super-
imposed on the DCA model at the 3s level.
(B) Structural comparison of the DCA-binding
site between PDK1-DCA (green) and apo-
PDK1 (pink). Residues in the unwound region
are shown in stick models.
(C) Superimposition of DCA-binding sites in the
structures of PDK1-DCA (green) and PDK2-
DCA (yellow) (PDB ID code 2BU8; Knoechel
et al., 2006). Residues surrounding the bound
DCA are shown in stick models. Only residue
numbers for PDK1 are shown. A stereo version
of this figure is provided in Figure S3.
(D) Interactions between helix a6 and the
lipoyl-binding pocket in the PDK1-DCA struc-
ture (green) superimposed with the apo-PDK1
(pink) and PDK1-AZD7545 (cyan) structures.
The bound DCA and AZD7545 are shown in
space-filling models. Interacting residues
from helix a6 and the lipoyl-binding pocket
are shown in stick models. AZD7545 binding
orders the loop region between helices a2
and a3.l rights reserved
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Structural Mechanisms for PDK InhibitorsTable 2. Averaged B Factors of the PDK1 Structures
Apo-PDK1 PDK1-DCA PDK1-AZD7545
B Factor (A2) Differencea (%) B Factor (A2) Differencea (%) B Factor (A2) Differencea (%)
Overall (residues 41–423) 52.7 — 43.9 — 29.5 —
Helix 6a (residues 132–146) 59.2 12.3 56.9 29.7 31.6 7.0
Helix 7a (residues 152–166) 51.1 2.9 42.6 2.8 30.0 1.6
B factors are calculated for the main-chain atoms of the indicated residue range.
a Relative differences of the averaged B factors against the overall value are calculated by the following equation: difference (%) =
(overall B factor  helix B factor)/overall B factor 3 100.(Kato et al., 2005; Tuganova et al., 2002). The intercalation
of AZD7545 in the lipoyl domain-binding pocket impedes
the anchoring of PDK3 to the E2p/E3BP core, and
prevents colocalization of the kinase to the bound E1p
substrate on the same scaffold. This results in a significant
inhibition of E1p phosphorylation due to substrate inac-
cessibility, despite the stimulation of basal PDK3 activity
by this compound. Thus, AZD7545 appears to be
a ‘‘dual-role’’ ligand for PDK3 by serving both as an
inhibitor and as a potent activator for this PDK isoform,
dependent on the presence and absence of the E2p/
E3BP core, respectively. The activator role of AZD7545
likely makes it a useful small molecule for investigating
the mechanism underlying the allosteric stimulation of
basal PDK3 activity.
DCA Binding Promotes Conformational Changes
at the Active-Site Cleft
PDK1 crystals soaked with DCA produced unambiguous
electron density for DCA in the Fo  Fc map of the
PDK1-DCA complex (Figure 5A). The DCA-binding site is
located inside the helix bundle in the N-terminal domain
of PDK1 and is completely shielded from solvent in the
apo-PDK1 structure. The shielded DCA-binding site may
be responsible for the low affinity of DCA for PDK isoforms
(Bowker-Kinley et al., 1998). When DCA enters the buried
binding site, a large conformational movement of the helix
bundle has to occur transiently to accommodate the
ligand. The side chain of His149 resides in the vicinity of
the DCA-binding site in apo-PDK1; but in the PDK1-DCA
structure, the boundDCA dislocates the His149 side chain
more than 6 A˚ toward the outside of the helix bundle
(Figure 5B). The movement of His149 promotes an
unwinding of the helical structure in the short segment
between Arg148 and Asp151. Consistent with the current
model for DCA binding, a very recent report has shown
that Arg114 and His115 in PDK2, which correspond to
Arg148 and His149 in PDK1, are crucial for the interaction
of PDK2 with DCA (Klyuyeva et al., 2007). Because this
segment connects helices a6 and a7, the conformational
change in this segment results in slight shifts (0.5 A˚) of
these helices in comparison to the corresponding helices
in apo-PDK1 (Figure 5B; Movie S1). The electron density
of helix a6 in the PDK1-DCA structure is poorer than that
of this helix in apo-PDK1 (data not shown). The averaged
B factor for helix a6 (residues 132–146) is 30% higher thanStructure 15, 992–the overall B factor, whereas a parallel match-up in the
apo structure shows only a 12% increase in B factor for
this region (Table 2). As helix a6 is not involved in crystal
packing, these results suggest that helix a6 is destabilized
by DCA binding. Significantly, the N-terminal region of
helix a6 interacts with the lipoyl-binding pocket through
an H-bonding network involving Thr139 on helix a6,
Glu72 and Ser75 on helix a3, and His198 on helix a8
(Figure 5D). These interactions could conceivably link
the stability state of helix a6 to that of the lipoyl-binding
pocket. In contrast with DCA, in the PDK1-AZD7545
structure, the increase in the averaged B factor for helix
a6 from the overall B factor is smaller (7%) than that in
the apo structure (Table 2), which suggests that
AZD7545 binding stabilizes the lipoyl-binding pocket
and thereby helix a6. Unlike helix a6, the stability of helix
a7 (residues 152–166) is not affected by DCA binding,
based also on B factor comparisons (Table 2).
We have shown that L2 binding promotes the opening
of the active-site cleft, which destabilizes the ATP lid
and facilitates ADP dissociation in the PDK3-L2 complex
(Kato et al., 2005). Kinetic studies have suggested that
the binding of DCA hinders the dissociation of ADP from
the active site, resulting in product inhibition (Bao et al.,
2004). The slower ADP release may be explained by the
slight relocation of helix a7 toward the ATP-binding site
in the PDK1-DCA structure, which likely restricts the
movement of the ATP lid (Movie S1). ADP binding to
PDK2 decreases the affinity of this kinase for L2 by
3-fold, and the presence of both ADP and DCA synergis-
tically reduces the affinity of PDK2 for L2 by over 130-fold,
compared to PDK2 alone (Hiromasa et al., 2006; Hiromasa
and Roche, 2003). Helices a6 and a7 in apo-PDK1 are
spatially juxtaposed and exist as a long helical rod that
connects the ATP-binding site and the lipoyl-binding
pocket (Movie S1). The signal of ADP binding at the
ATP-binding site can be transmitted through this helical
rod. As the DCA-binding site is located in the middle of
this rod, DCA may play the role of an amplifier for the sig-
nal triggered by the bound ADP. The segment between
helices a6 and a7 forms part of the active-site cleft of
PDK1; therefore, the unwound conformation in this
segment, as a result of DCA binding, may also decrease
kinase activity by thwarting the binding of the E1p sub-
strate to the kinase. In this context, the structure of an
asymmetric PDK3-L2 complex harboring only one bound1004, August 2007 ª2007 Elsevier Ltd All rights reserved 999
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Structural Mechanisms for PDK InhibitorsFigure 6. Structure of the Radicicol-Binding Site in PDK3-L2
(A) The omit electron density map of radicicol bound to PDK3. The density is superimposed on the refinedmodel of radicicol at the 3s level in blue and
the 9s level in red.
(B) Interactions between PDK3 residues and radicicol. H bonds are indicated by dashed lines. Water molecules are depicted as red balls.
(C) Comparison between radicicol and ATP bound to PDK3. The structure of PDK3-L2-ATP (PDB ID code 1Y8P; Kato et al., 2005) (magenta) is super-
imposed on PDK3-L2-radicicol (cyan).
(D) Superimposition of radicicol molecules bound to PDK1 (cyan), Hsp90 (PDB ID code 1BGQ; Roe et al., 1999) (pink), and Topo VI (PDB ID code
2HKJ; Corbett and Berger, 2005) (yellow). The three structures were superimposed based on the corresponding residues shown in the figure. Stereo
figures of (B)–(D) are provided in Figure S4.
(E) Comparison of the shape of the radicicol-binding pockets of PDK3, Hsp90, and Topo VI. The electrostatic surface of each protein is shownwith the
negative charge in red and the positive charge in blue.L2 domain has been recently reported (Devedjiev et al.,
2007). In this structure, a corresponding unwound ‘‘loop-
ing-out’’ segment is present in the L2-bound subunit of
the PDK3 dimer, resulting in narrowing of the active-site
cleft by 6 A˚ in the same subunit. These authors hypothe-1000 Structure 15, 992–1004, August 2007 ª2007 Elsevier Ltd Asize that the L2-bound PDK3 subunit is inactivated by
this perturbation of the active-site cleft, which impedes
the access of the E1p substrate. Reciprocally, the L2-
free PDK3 subunit in the PDK3 dimer is activated through
the opening of the active-site cleft promoted by thell rights reserved
Structure
Structural Mechanisms for PDK Inhibitorsinteractions between the fully ordered C-terminal tail from
this monomer and the lipoyl-binding pocket in the L2-
bound PDK3 subunit.
Radicicol Binds to the Nucleotide-Binding
Site of Human PDK3
As shown in Figure 6 and Figure S1, radicicol binds to the
ATP-binding site in the C-terminal domain of PDK3, but
the bound radicicol does not cause any structural change
in the PDK3 and L2 molecules of the PDK3-L2 complex.
The ATP lid is largely disordered, similar to that seen in
the structure of the PDK3-L2-ADP complex (Kato et al.,
2005). These results establish that radicicol inhibits
PDK3 activity by competing with ATP for the nucleotide-
binding site of the kinase (Figure 2).
Sequence identities between the C-terminal domain of
PDK3 and the GHKL domains of Hsp90 and Topo VI are
only 7%–12%. Despite the low sequence identities, the
folding of these GHKL domains is similar (Figure 7). Out
of 150–160 residues in these GHKL domains, 85 residues
from PDK3 are superimposable with the corresponding
residues in Hsp90, with an rmsd of 1.6 A˚. For Topo VI,
84 residues from PDK3 are superimposable, with an
rmsd of 1.5 A˚. In the PDK3-L2-radicicol structure, all
hydroxyl and carbonyl groups of the bound radicicol
participate in forming direct or indirect H bonds with resi-
dues in the ATP-binding site (Figure 6B). In particular, an
H-bonding network involving three water molecules and
Asp287 as well as Thr352 of PDK3 is conserved in the
GHKL proteins (Figure 6D). This conserved H-bonding
network is important for PDK3 to recognize the adenine
Figure 7. Radicicol-BindingSites inPDK3,Hsp90, andTopoVI
Structures of PDK3 (cyan), Hsp90 (PDB ID code 1BGQ; Roe et al.,
1999) (pink), and Topo VI (PDB ID code 2HKJ; Corbett and Berger,
2005) (yellow) are superimposed based on the conserved residues in
the nucleotide-binding site (see Figure 6D). The sole radicicol molecule
from PDK3-L2-radicicol is shown in a stickmodel. Residues discussed
in the text are shown as stick models.Structure 15, 992–10base of the bound ATP (Figure 6C). A substitution of
Asp288 in PDK2 corresponding to Asp287 of PDK3 abol-
ishes ATP binding by PDK2 (Bowker-Kinley and Popov,
1999). Thus, the present results establish that this
H-bonding network is a key determinant for radicicol bind-
ing to GHKL proteins.
Radicicol inhibits Hsp90 effectively, with an estimated
IC50 value of less than 1 mM (Roe et al., 1999). By compar-
ison, an apparent IC50 of radicicol for Topo VI is much
higher, approximated at 100 mM with the maximal inhibi-
tion achieved at 500 mM (Corbett and Berger, 2005). The
latter IC50 value for radicicol is in the range of those
estimated for PDK1 (400 mM) and PDK3 (230 mM)
(Figure 2B) and the apparent Ki of 23 mM determined for
PDK2 (Tuganova et al., 2001). These results indicate that
the affinity of radicicol for Hsp90 is at least 100-fold higher
than that for Topo VI and PDK isoforms. From a structural
viewpoint, the side chain of Lys44 in Hsp90 is present as
an overhang outside the radicicol-binding pocket and
forms a direct H bond with the epoxide oxygen of radici-
col, which locks the inhibitor in place (Figure 6E) (Roe
et al., 1999). In contrast, Topo VI has only an indirect
H bond with this oxygen from residue His50 of this protein
(Corbett and Berger, 2005), whereas an equivalent H bond
is absent in PDK3 (Figure 7). The binding-site entrances in
both proteins are wide open (Figure 6E), which is likely to
facilitate the dissociation of bound radicicol. Thus, it is
plausible that Lys44 in Hsp90 serves as the specific deter-
minant that confers the higher affinity of Hsp90 for radici-
col over Topo VI and PDK3. Along the same lines, Arg254
in PDK3 that projects over the bound radicicol may play
a similar role to Lys44 in Hsp90 (Figure 6E). This arginine
residue is completely conserved in the PDK family, but is
not present in otherGHKLproteins (Figure 7). Thus, amod-
ified radicicol with the epoxide oxygen translocated within
the macrocyclic ring to be close to the invariant Arg254 for
H-bond formation may show higher affinity for kinases of
the PDK family.
EXPERIMENTAL PROCEDURES
Assays for Inhibition of PDK Activities
To determine the IC50 of AZD7545 for PDK1 and PDK3, a mixture
containing 50 nM SUMO-PDK1 or SUMO-PDK3, 1.5 mM E1p, 50 nM
E2/E3BP core, and different amounts of AZD7545 was incubated at
25C for 30 min in a phosphorylation buffer of 20 mM potassium phos-
phate (pH 7.5), 50mMKCl, 2mMMgCl2, and 2mMdithiothreitol (DTT).
A slightly different condition was used during determination of the IC50
of radicicol for PDK1 and PDK3, in which 0.56 mM SUMO-PDK1 or
0.28 mM SUMO-PDK3, 6.4 mM E1p, 2.3 mM E2/E3BP core, and differ-
ent amounts of radicicol were incubated. The AZD7545 and radicicol
stock solutions were prepared in 100% DMSO and diluted into the
assay mixture to a 2% final DMSO concentration. The presence of
a SUMO tag is necessary to maintain the solubility of PDK1 and
PDK3 and has no effect on kinase activity. The phosphorylation reac-
tion was initiated by adding [g-32P]ATP (specific activity 0.5 mCi/nmol
ATP) to a 50 mM (for AZD7545 IC50 determination) or 100 mM (for rad-
icicol IC50 determination) final concentration in a total reaction volume
of 60 ml. The reaction was terminated at 1 min intervals by withdrawing
15 ml of the reaction mixture and mixing it immediately with 5 ml of the
43 concentrated SDS-PAGE loading buffer containing 100 mM EDTA.
The reactionmixture was heated at 65C for 10min and then applied to04, August 2007 ª2007 Elsevier Ltd All rights reserved 1001
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Structural Mechanisms for PDK Inhibitorsan SDS-PAGE gel, followed by phosphorimaging analyses. The phos-
phorylation level was quantified using a Typhoon 9200 variable-mode
imager (Pharmacia, Piscataway, NJ, USA) by comparison with
standards. PDK activities with the inhibitors were normalized against
control activities without inhibitors. Data analyses and curve fittings
were carried out using the Prism program (GraphPad Software, San
Diego, CA, USA). To determine the maximal inhibitory levels of PDK
inhibitors in the absence and presence of the E2p/E3BP core, a satu-
rating concentration of each inhibitor (10 mM AZD7545, 40 mM DCA,
and 4 mM radicicol) was incubated with 50 nM SUMO-PDK1 or
SUMO-PDK3, and 1.5 mM E1p with or without 50 nM E2/E3BP core
at 25C for 30 min. The reaction was initiated by adding [g-32P]ATP
to a 50 mM final concentration in a total volume of 60 ml. The reaction
was terminated at 60 s, followed by SDS-PAGE and phosphorimaging
analyses as described above.
Crystallization and Structure Determination
Crystals were obtained using the hanging-drop vapor-diffusion
method by mixing 2 ml of PDK1 solution (50 mg/ml untagged PDK1
in 50 mM potassium phosphate [pH 7.5], 250 mM KCl, 800 mM lysine,
5% glycerol, and 20 mM DTT) with 2 ml of well solution (0.42 M Na-K
tartrate, 0.1 M Na citrate [pH 5.6]) and kept at 20C. The high PDK1
concentration required for crystallization was achieved by the
inclusion of 800 mM lysine in the protein solution. Dilution seeding
was used to induce nucleation. Single crystals grew to 500 3 500 3
500 mm in size within a week. Crystals were transferred to fresh well
solution for 18–24 hr and soaked in well solution containing 50 mM
DCA or 0.1mMAZD7545 for 30min. These crystals were serially trans-
ferred to well solution containing 25% glycerol and flash-frozen in
liquid propane. Crystals of the PDK3-L2-radicicol complex were pre-
pared by soaking those of the apo-PDK3-L2 complex (Kato et al.,
2005) with 1mM radicicol. Diffraction data were collected at beamlines
19ID and 19BM at the Structural Biology Center at the Advanced
Photon Source (Argonne, IL, USA). The data were processed with
HKL2000 (Otwinowski and Minor, 1997).
The PDK1 structures were solved by molecular replacement using
the program Phaser (Read, 2001) in the CCP4 package (CCP4,
1994). A PDK1 model based on the published PDK3 structure (Protein
Data Bank [PDB] ID code 1Y8N; Kato et al., 2005) was constructed
using a homology-modeling technique in the SWISS-MODEL program
(Schwede et al., 2003). After rigid-body refinements with REFMAC5
(Murshudov et al., 1997), the electron density mapwas improved using
DM (Cowtan and Main, 1996). The Fo  Fc maps unambiguously
showed the electron density of the inhibitors in individual crystals
soaked with AZD7545 and DCA. After modeling the inhibitors, water
molecules were gradually added in subsequent refinement cycles.
The structure of PDK3-L2-radicicol was solved by the difference Four-
ier method using the published structure of PDK3-L2 (PDB ID code
1Y8P; Kato et al., 2005) as a starting model. The refinement was car-
ried out as described for the PDK1 refinement. Data processing and
refinement statistics are summarized in Table 1. Molecular graphics
for structural representations were drawn by PyMOL (DeLano Scien-
tific LLC, Palo Alto, CA, USA).
Supplemental Data
Supplemental Data include four figures, one movie, and Supplemental
Experimental Procedures for protein expression, purification, and
SUMO-tag removal for crystallization and can be found with this article
online at http://www.structure.org/cgi/content/full/15/8/992/DC1/.
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